The monoclonal antibody-defined CARS antigen is a new carcinoma associated marker which is expressed on a mucin-like molecule. Serum concentrations of CARS were assayed in 181 patients with carcinomas of different organs, 20 patients with non-carcinomatous malignancies, 123 patients with inflammatory diseases and 150 healthy controls. Serum levels of CARS were significantly increased in 51% of the patients with pancreatic carcinomas, in 60% of patients with biliary tract carcinomas and in about 15% of the patients with carcinomas of the digestive apparatus. Sera from patients with breast carcinomas were negative, as well as sera from patients with melanomas or sarcomas. CAR-3 values in samples from patients with chronic pancreatitis were constantly negative, as were samples from healthy donors. Significant concentrations of CAR-3 were detected in 20% of the sera from patients with acute pancreatitis and in 15% of the sera from patients with cirrhosis. Because of its high specificity for pancreatic carcinomas compared to chronic pancreatitis, CARS seems a promising marker for distinguishing between neoplastic and chronic inflammatory diseases of the pancreas, whose differential diagnosis is difficult.
KoprowskiH., HerlynD., SteplewskiZ., SearsH.F.Specific antigen in serum of patients with colon carcinoma. Science1981; 212: 53–5.
2.
HolgremJ., LindholmL., PerssonB.Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J1984; 288: 1479–82.
3.
Del VillanoB.C., BrennanS., BrockP.Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem1983; 29: 549–52.
4.
BastR.C., KlugT.L., St. JohnE.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med1983; 309: 883–7.
5.
MetzgarR.S., RodriguezN., FinnO.J.Detection of a pancreatic cancer-associated antigen (DUPAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA1984; 81: 5242–6.
6.
BurchellJ., WangD., Taylor-PapadimitriouJ.Detection of the tumor associated antigens recognized by the monoclonal antibodies HMFG1 and 2 in serum from patients with breast cancer. Int J Cancer1984; 34: 763–8.
7.
HilkensJ., KroezenV., BonfrerJ.M.B.MAM-6, a new serum marker for breast cancer monitoring. Cancer Res1986; 46: 2582–7.
8.
PatersonA.J., SchlomJ., SearsH.F.Radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int J Cancer1986; 37: 659–66.
9.
MiottiS., AguannoS., CanevariS.Biochemical analysis of human ovarian cancer-associated antigens defined by murine monoclonal antibodies. Cancer Res1985; 45: 826–32.
10.
KlugT.L., SattlerM.A., ColcherD., SchlomJ.Monoclonal antibody immunometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer1986; 38: 661–9.
11.
SawabuN., ToyaD., TakemoriY.Measurement of a pancreatic cancer-associated antigen (DUPAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Int J Cancer1986; 37: 693–6.
12.
HaglundC., KuuselaP., JalankoH., RobertsP.J.Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19–9. Int J Cancer1987; 39: 477–81.
13.
WardB.G., CruickshankD.J.Circulating tumor-associated antigen detected by the monoclonal antibody HMFG2 in human epithelial ovarian cancer. Int J Cancer1987; 39: 30–3.
14.
PratM., BussolatiG., SpinnatoM.R., ComoglioP.M.Monoclonal antibodies against the human epidermoid carcinoma A 431. Cancer Detec Prevention1985; 8: 169–79.
15.
PratM., MorraI., BussolatiG., ComoglioP.M.CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas. Cancer Res1985; 45: 5799–807.
16.
PratM., GriselliB., BernardiA.Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa. Eur J Cancer Clin Oncol1987; 23: 923–32.
17.
MagnaniJ.L., SteplewskiZ., KoprowskiH., GinsburgV.Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res1983; 43: 5489–92.
18.
JohnsonV.G., SchlomJ., PatersonA.J.Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res1986; 46: 850–7.
19.
EyP.L., ProwseS.J., JenkinC.R.Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry1978; 15: 429–36.
20.
PratM., ComoglioP.M.A solid-state competitive binding radioimmunoassay for measurement of antigens solubilized from membranes. J Immunol Methods1976; 9: 267–72.
21.
FoghJ., TrempeG.New human tumor cell lines. Human tumor cell in vitro, FoghJ. ed, Plenum Publishing Corp1975; 115–38.
22.
PapsideroL.D., JohnsonE.Physicochemical purification and immunological characterization of ductal carcinoma antigen. Int J Cancer1986; 37: 697–703.
23.
MiottiS., CanevariS., MenardS.Characterization of ductal human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Caner1987; 39: 297–303.
24.
LinsleyP.S., OchsV., LaskaS.Elevated levels of sera of high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Res1986; 46: 5444–50.
25.
JalankoH., KuuselaP., RobertP.Comparison of a new tumour marker, CA 19-9 TM, with α-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol1984; 37: 218–22.
26.
BucheggerF., MettrauxC., AccollaR.S.Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of CEA. Immunol Lett1982; 5: 85–91.
27.
LindgrenJ., BangB., HurmeM., MakelaO.Monoclonal antibodies to carcinoembryonic antigen (CEA): characterization and use in a radioimmunoassay for CEA. Acta Pathol Microbiol Immunol Scand1982; 90: 159–62.
28.
RittsE.R., Del VillanoB.C., GoV.L.W.Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer1984; 33: 339–45.
29.
HabibN.A., HershmanM.J., HaberlandF.The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br J Cancer1986; 53: 697–9.
30.
HaglundC., RobertsP., KuuselaP.Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer. Br J Cancer1986; 53: 197–202.
31.
GalenR.S., GambinoS.R.Beyond Normality. The Predictive Value and Efficiency of Medical Diagnosis, John Wiley & Sons, New York, NY, 1977.
